-
ADVENTRX Receives Positive SeekingAlpha Mention (ANX)
Wednesday, May 4, 2011 - 7:16pm | 92ADVENTRX (NASDAQ: ANX) has received a positive SeekingAlpha mention in an article that can be found here. The article mentions the company's likely "run-up" prior to a September 1st FDA decision date. The author, who discloses a long position in ADVENTRX, says, "I think the stock could trade...
-
Oncothyreon Announces Exercise of Underwriters' Over-Allotment Option and Closing of $46.0 Million Public Offering of Common Stock (ONTY)
Wednesday, May 4, 2011 - 4:11pm | 94Oncothyreon Inc. (NASDAQ: ONTY) today announced that it has closed an underwritten public offering of 11,500,000 shares of its common stock at a price to the public of $4.00 per share for gross proceeds of $46.0 million. The shares include 1,500,000 shares of common stock sold pursuant to the over-...
-
Healthcare Round Up: Dendrean Falls From Grace
Wednesday, May 4, 2011 - 3:44pm | 408Healthcare trading lower with the broader market today and once again the small caps weighing on the performance of the broader group as investors look to take profits in the recent outperformers. Biotechs, tools, managed care and facilities, four of the best performing subsectors in the group YTD...
-
Dendreon Corporation (DNDN) Citibank is Expecting -16% Downside From Here
Wednesday, May 4, 2011 - 3:37pm | 598Citibank believe a Speculative (S) risk rating for Dendreon is appropriate, given the price volatility and the risk associated with PROVENGE launch. As with any development-stage biopharmaceutical company, investing in Dendreon involves many commercial, intellectual property (IP) and...
-
Biotech and Pharma News; BioSante Pharmaceuticals, Inc. To Present at JMP Securities Research Conference
Wednesday, May 4, 2011 - 2:44pm | 542LINCOLNSHIRE, Ill. - May 4, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will be presenting at The JMP Securities Tenth Annual Research Conference. The event will take place from May 9, through May 11, 2011, at The Ritz-Carlton, San Francisco. Stephen M. Simes...
-
Options Brief: PharmAthene, Inc. (PIP)
Wednesday, May 4, 2011 - 2:37pm | 71Shares of PharmAthene, Inc. (AMEX: PIP) are higher on the session by 5.62%, trading at $3.76. Overall call volume is now running at 3.98x the daily average, with 76% of all calls traded being purchases on the offer. 2,071 contracts have traded on the session so far. PharmAthene, Inc. is a...
-
Goldman Sachs Upgrades PT On Myriad Genetics To $19, Maintains Sell (MYGN)
Wednesday, May 4, 2011 - 12:44pm | 160Goldman Sachs upgraded its prices target on Myriad Genetics (NASDAQ: MYGN) in a research report published today. Goldman also upgraded its earnings per share forecast, after better than expected Q1 results, but reiterated its Sell rating on Myriad. In the report, Goldman states, "MYGN reported...
-
May Catalysts for Biotech and Drug Stocks
Wednesday, May 4, 2011 - 12:32pm | 557By Brett Chase After a few months of blockbuster Food and Drug Administration advisory panel meetings, May seems a bit calmer. But there are certainly important dates for drug and biotechnolgy companies. Here are some events to watch for this month. Dates are subject to change. May 3 Vertex...
-
Safety Monitoring Committee Meeting Positive for Nymox Pivotal Phase 3 NX-1207 Trials
Wednesday, May 4, 2011 - 10:45am | 66Nymox Pharmaceutical Corporation (Nasdaq: NYMX) provided a further update today on the Company's ongoing Phase 3 trials for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia. The Safety Monitoring Committee meeting of May 3, 2011 found no significant safety concerns to date for...
-
CEL-SCI Corporation Receives Government Approval in Poland to Commence Phase III Clinical Trial of Multikine in Head and Neck Cancer
Wednesday, May 4, 2011 - 9:59am | 131CEL-SCI Corporation (NYSE: CVM) announced today that it has received approval to begin enrollment of patients in its Phase III clinical trial of Multikine® from the Polish Minister of Health. This approval marks a very important milestone, namely that all nine countries in the study have now given...
-
Jefferies On New Study From CELG
Wednesday, May 4, 2011 - 9:42am | 105Jefferies has issued a report regarding the new study from Celgene Corp (NASDAQ: CELG). According to the report, "In advance of tomorrow's main update on the three Revlimid maintenance trials, we have learned that the French IFM study will show the first signs of a trend towards an overall...
-
Goldman Sachs Has Sell Rating On Myriad Genetics (MYGN)
Wednesday, May 4, 2011 - 9:01am | 149Goldman Sachs has a Sell rating and a $19 price target on shares of Myriad Genetics (NASDAQ: MYGN) following Myriad's earnings. In a note to investors, Goldman writes, "F3Q11 results revealed improved fundamentals in MYGN's core BRCA business as patient office visit trends stabilized and recent...
-
Pharma News; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) To Present at JMP Securities Research Conference
Wednesday, May 4, 2011 - 9:00am | 24LINCOLNSHIRE, Ill. - May 4, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) will be presenting at The JMP Securities Tenth Annual Research Conference.
-
Pharma News; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) To Present at JMP Securities Research Conference
Wednesday, May 4, 2011 - 9:00am | 24LINCOLNSHIRE, Ill. - May 4, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) will be presenting at The JMP Securities Tenth Annual Research Conference.
-
Keryx Biopharmaceuticals Prices Common Stock Offering at 4.70 per Share
Wednesday, May 4, 2011 - 8:55am | 34Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) today announced the pricing of an underwritten registered offering of 7,021,277 shares of its common stock at a price of $4.70 per share.